Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 16 | 2020 | 414 | 4.440 |
Why?
|
| Bronchoscopy | 10 | 2018 | 47 | 2.040 |
Why?
|
| Early Detection of Cancer | 6 | 2020 | 93 | 1.790 |
Why?
|
| Pulmonary Medicine | 2 | 2015 | 11 | 1.000 |
Why?
|
| Endosonography | 2 | 2015 | 56 | 0.970 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2017 | 145 | 0.940 |
Why?
|
| Lymph Nodes | 2 | 2016 | 107 | 0.920 |
Why?
|
| Clinical Competence | 2 | 2015 | 333 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 101 | 0.750 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 53 | 0.730 |
Why?
|
| Decision Making | 2 | 2019 | 195 | 0.690 |
Why?
|
| Health Services | 1 | 2019 | 39 | 0.670 |
Why?
|
| Social Class | 1 | 2019 | 90 | 0.670 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 881 | 0.660 |
Why?
|
| Middle Aged | 18 | 2020 | 11839 | 0.640 |
Why?
|
| Patient Compliance | 1 | 2020 | 225 | 0.640 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 20 | 0.640 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 35 | 0.640 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 55 | 0.620 |
Why?
|
| Attitude to Health | 1 | 2019 | 166 | 0.610 |
Why?
|
| Lymphoma | 1 | 2018 | 35 | 0.610 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 128 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 169 | 0.580 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2017 | 6 | 0.580 |
Why?
|
| Cough | 1 | 2017 | 19 | 0.570 |
Why?
|
| Aged | 14 | 2020 | 10314 | 0.570 |
Why?
|
| Ethnic Groups | 1 | 2019 | 476 | 0.560 |
Why?
|
| Granuloma | 1 | 2016 | 14 | 0.540 |
Why?
|
| Postoperative Complications | 2 | 2017 | 780 | 0.490 |
Why?
|
| Male | 17 | 2020 | 19217 | 0.490 |
Why?
|
| Female | 18 | 2020 | 20015 | 0.490 |
Why?
|
| Humans | 22 | 2020 | 32114 | 0.470 |
Why?
|
| Asthma | 1 | 2017 | 259 | 0.470 |
Why?
|
| Mediastinal Diseases | 1 | 2012 | 4 | 0.430 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 93 | 0.420 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 53 | 0.410 |
Why?
|
| Neoplasms | 1 | 2016 | 728 | 0.320 |
Why?
|
| Conscious Sedation | 2 | 2017 | 24 | 0.280 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3510 | 0.270 |
Why?
|
| Mass Screening | 2 | 2019 | 263 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 919 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2020 | 2283 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3990 | 0.240 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 876 | 0.240 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 447 | 0.240 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 166 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 158 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2018 | 1817 | 0.220 |
Why?
|
| Bronchial Neoplasms | 2 | 2013 | 5 | 0.200 |
Why?
|
| Consumer Health Information | 1 | 2019 | 12 | 0.170 |
Why?
|
| Computers, Handheld | 1 | 2019 | 15 | 0.170 |
Why?
|
| Information Seeking Behavior | 1 | 2019 | 11 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 44 | 0.170 |
Why?
|
| Income | 1 | 2019 | 63 | 0.170 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Educational Status | 1 | 2019 | 181 | 0.160 |
Why?
|
| Access to Information | 1 | 2019 | 13 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 45 | 0.160 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.160 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 20 | 0.160 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 20 | 0.160 |
Why?
|
| Lung | 1 | 2020 | 249 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2018 | 97 | 0.160 |
Why?
|
| Adult | 5 | 2018 | 9380 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 162 | 0.150 |
Why?
|
| Decision Trees | 1 | 2018 | 31 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 684 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2017 | 29 | 0.150 |
Why?
|
| Cholinergic Antagonists | 1 | 2017 | 10 | 0.150 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 9 | 0.150 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 13 | 0.150 |
Why?
|
| Vital Capacity | 1 | 2017 | 40 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 54 | 0.140 |
Why?
|
| Prednisolone | 1 | 2017 | 9 | 0.140 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 87 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 733 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 59 | 0.140 |
Why?
|
| Midazolam | 1 | 2016 | 10 | 0.140 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 100 | 0.140 |
Why?
|
| Bronchodilator Agents | 1 | 2017 | 49 | 0.140 |
Why?
|
| Anesthetics, Intravenous | 1 | 2016 | 17 | 0.140 |
Why?
|
| Fentanyl | 1 | 2016 | 32 | 0.140 |
Why?
|
| Smoking | 1 | 2020 | 528 | 0.140 |
Why?
|
| Mediastinum | 1 | 2016 | 14 | 0.140 |
Why?
|
| False Negative Reactions | 1 | 2016 | 20 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 58 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 259 | 0.130 |
Why?
|
| United States | 3 | 2020 | 3976 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 122 | 0.130 |
Why?
|
| Outpatients | 1 | 2015 | 57 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2015 | 10 | 0.120 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1166 | 0.120 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 10 | 0.120 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 13 | 0.120 |
Why?
|
| Palliative Care | 1 | 2015 | 52 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2017 | 898 | 0.120 |
Why?
|
| Leiomyoma | 2 | 2013 | 16 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 127 | 0.110 |
Why?
|
| Hispanic Americans | 1 | 2019 | 940 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2019 | 1429 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 184 | 0.110 |
Why?
|
| Cryotherapy | 1 | 2013 | 13 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 638 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 130 | 0.110 |
Why?
|
| African Americans | 1 | 2019 | 1425 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 408 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 297 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 464 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 357 | 0.100 |
Why?
|
| Young Adult | 1 | 2018 | 2665 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 367 | 0.090 |
Why?
|
| Obesity | 1 | 2016 | 1176 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2019 | 294 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 59 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2019 | 51 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 206 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 108 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 261 | 0.040 |
Why?
|
| Internet | 1 | 2019 | 198 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 276 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 321 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 31 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 877 | 0.030 |
Why?
|
| Neck | 1 | 2016 | 27 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 308 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 315 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 84 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1497 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 376 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2265 | 0.030 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2013 | 2 | 0.030 |
Why?
|
| Granular Cell Tumor | 1 | 2013 | 2 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 2013 | 4 | 0.030 |
Why?
|
| Papilloma | 1 | 2013 | 9 | 0.030 |
Why?
|
| Hamartoma | 1 | 2013 | 10 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 923 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3306 | 0.020 |
Why?
|